Developing Selective Media for Quantification of Multispecies Biofilms Following Antibiotic Treatment

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Nov 10

PMID 29121069

Citations 16

Authors

Eva Vandeplassche

Tom Coenye

Aurelie Crabbe

Affiliations

Soon will be listed here.

Abstract

The lungs of cystic fibrosis (CF) patients are chronically colonized by a polymicrobial biofilm community, leading to difficult-to-treat infections. To combat these infections, CF patients are commonly treated with a variety of antibiotics. Understanding the dynamics of polymicrobial community composition in response to antibiotic therapy is essential in the search for novel therapies. Culture-dependent quantification of individual bacteria from defined multispecies biofilms is frequently carried out by plating on selective media. However, the influence of the selective agents in these media on quantitative recovery before or after antibiotic treatment is often unknown. In the present study we developed selective media for six bacterial species that are frequently co-isolated from the CF lung, i.e. Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus anginosus, Achromobacter xylosoxidans, Rothia mucilaginosa, and Gemella haemolysans. We show that certain supplementations to selective media strongly influence quantitative recovery of (un)treated biofilms. Hence, the developed media were optimized for selectivity and quantitative recovery before or after treatment with antibiotics of four major classes, i.e. ceftazidime, ciprofloxacin, colistin, or tobramycin. Finally, in a proof of concept experiment the novel selective media were applied to determine the community composition of multispecies biofilms before and after treatment with tobramycin.

Citing Articles

Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model.

Varga J, Zhao C, Davis J, Hao Y, Farrell J, Gurney J mSphere. 2022; 7(5):e0031822.

PMID: 35972133 PMC: 9599657. DOI: 10.1128/msphere.00318-22.

Microbial diversity and antimicrobial susceptibility in endotracheal tube biofilms recovered from mechanically ventilated COVID-19 patients.

van Charante F, Wieme A, Rigole P, De Canck E, Ostyn L, Grassi L Biofilm. 2022; 4:100079.

PMID: 35720435 PMC: 9192360. DOI: 10.1016/j.bioflm.2022.100079.

is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.

Rigauts C, Aizawa J, Taylor S, Rogers G, Govaerts M, Cos P Eur Respir J. 2021; 59(5).

PMID: 34588194 PMC: 9068977. DOI: 10.1183/13993003.01293-2021.

Dissecting Individual Interactions between Pathogenic and Commensal Bacteria within a Multispecies Gut Microbial Community.

Hassall J, Cheng J, Unnikrishnan M mSphere. 2021; 6(2).

PMID: 33762315 PMC: 8546675. DOI: 10.1128/mSphere.00013-21.

Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm.

Vandeplassche E, Sass A, Ostyn L, Burmolle M, Kragh K, Bjarnsholt T Biofilm. 2021; 2:100031.

PMID: 33447816 PMC: 7798459. DOI: 10.1016/j.bioflm.2020.100031.

References

Filkins L, OToole G . Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat. PLoS Pathog. 2016; 11(12):e1005258. PMC: 4700991. DOI: 10.1371/journal.ppat.1005258. View

Mahenthiralingam E . Emerging cystic fibrosis pathogens and the microbiome. Paediatr Respir Rev. 2014; 15 Suppl 1:13-5. DOI: 10.1016/j.prrv.2014.04.006. View

Ciofu O, Tolker-Nielsen T, Jensen P, Wang H, Hoiby N . Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. 2014; 85:7-23. DOI: 10.1016/j.addr.2014.11.017. View

Amoureux L, Bador J, Fardeheb S, Mabille C, Couchot C, Massip C . Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013; 79(23):7142-9. PMC: 3837737. DOI: 10.1128/AEM.02293-13. View

Sibley C, Surette M . The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture. Can J Microbiol. 2011; 57(2):69-77. DOI: 10.1139/w10-105. View

Soyza A, Hall A, Mahenthiralingam E, Drevinek P, Kaca W, Drulis-Kawa Z . Developing an international Pseudomonas aeruginosa reference panel. Microbiologyopen. 2013; 2(6):1010-23. PMC: 3892346. DOI: 10.1002/mbo3.141. View

Lopes S, Ceri H, Azevedo N, Pereira M . Antibiotic resistance of mixed biofilms in cystic fibrosis: impact of emerging microorganisms on treatment of infection. Int J Antimicrob Agents. 2012; 40(3):260-3. DOI: 10.1016/j.ijantimicag.2012.04.020. View

Van den Driessche F, Rigole P, Brackman G, Coenye T . Optimization of resazurin-based viability staining for quantification of microbial biofilms. J Microbiol Methods. 2013; 98:31-4. DOI: 10.1016/j.mimet.2013.12.011. View

Sawant A, Pillai S, Jayarao B . Evaluation of five selective media for isolation of catalase-negative gram-positive cocci from bulk tank milk. J Dairy Sci. 2002; 85(5):1127-32. DOI: 10.3168/jds.S0022-0302(02)74174-X. View

10.

Brayshaw D . Methicillin-resistant Staphylococcus aureus: evaluation of detection techniques on laboratory-passaged organisms. Br J Biomed Sci. 2000; 56(3):170-6. View

11.

Caverly L, Zhao J, LiPuma J . Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection. Pediatr Pulmonol. 2015; 50 Suppl 40:S31-8. DOI: 10.1002/ppul.23243. View

12.

Sibley C, Grinwis M, Field T, Eshaghurshan C, Faria M, Dowd S . Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One. 2011; 6(7):e22702. PMC: 3145661. DOI: 10.1371/journal.pone.0022702. View

13.

Chuanchuen R, Karkhoff-Schweizer R, Schweizer H . High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect Control. 2003; 31(2):124-7. DOI: 10.1067/mic.2003.11. View

14.

Ho P, Ho L, Yau C, Tong M, Chow K . A Novel Selective Medium for Isolation of Bacteroides fragilis from Clinical Specimens. J Clin Microbiol. 2016; 55(2):384-390. PMC: 5277507. DOI: 10.1128/JCM.01988-16. View

15.

OConnell H, Kottkamp G, Eppelbaum J, Stubblefield B, Gilbert S, Gilbert E . Influences of biofilm structure and antibiotic resistance mechanisms on indirect pathogenicity in a model polymicrobial biofilm. Appl Environ Microbiol. 2006; 72(7):5013-9. PMC: 1489306. DOI: 10.1128/AEM.02474-05. View

16.

PARFENTJEV I, CATELLI A . TOLERANCE OF STAPHYLOCOCCUS AUREUS TO SODIUM CHLORIDE. J Bacteriol. 1964; 88:1-3. PMC: 277246. DOI: 10.1128/jb.88.1.1-3.1964. View

17.

Hoiby N, Bjarnsholt T, Moser C, Jensen P, Kolpen M, Qvist T . Diagnosis of biofilm infections in cystic fibrosis patients. APMIS. 2017; 125(4):339-343. DOI: 10.1111/apm.12689. View

18.

Takada K, Hirasawa M . A novel selective medium for isolation of Streptococcus mutans. J Microbiol Methods. 2004; 60(2):189-93. DOI: 10.1016/j.mimet.2004.09.009. View

19.

Zhao J, Schloss P, Kalikin L, Carmody L, Foster B, Petrosino J . Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 2012; 109(15):5809-14. PMC: 3326496. DOI: 10.1073/pnas.1120577109. View

20.

Huang Y, LiPuma J . The Microbiome in Cystic Fibrosis. Clin Chest Med. 2016; 37(1):59-67. PMC: 5154676. DOI: 10.1016/j.ccm.2015.10.003. View